Eli Lilly's oral GLP-1 Foundayo beats oral semaglutide in three diabetes trials with 57.1% greater A1C reduction and 73.6% greater weight loss at 17.2 mg. FDA submission targeted by end of Q2.

Gilead and Merck announce positive Phase 3 results for once-weekly oral HIV treatment islatravir/lenacapavir, meeting primary efficacy endpoints at week 48 in both ISLEND-1 and ISLEND-2 trials.

Gilead and Merck reported positive Phase 3 results for the once-weekly oral HIV treatment islatravir/lenacapavir, with primary efficacy endpoints met at week 48 in both the ISLEND-1 and ISLEND-2 trials.

AstraZeneca obesity pill cuts weight by 11.8% in mid-stage trial, drugmaker pushes into booming weight-loss market

AstraZeneca's experimental obesity pill helped patients lose up to 11.8% of their body weight in a mid-stage trial, as the British drugmaker pushes into the surging weight-loss drug market.

AstraZeneca advances oral GLP-1 drug elecoglipron to Phase III trials, moving the once-daily candidate into late-stage development for metabolic disease.

AstraZeneca advances its oral GLP-1 drug elecoglipron to Phase III trials.

DRC Ebola death toll tops 100, health ministry says — total infections reach 550 in ongoing outbreak.

In the DRC, the number of deaths from Ebola has exceeded 100, the African country's health ministry reported. The number of infected has reached 550.